Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.

Original publication

DOI

10.1016/j.jacc.2017.08.037

Type

Journal article

Journal

J Am Coll Cardiol

Publication Date

03/10/2017

Volume

70

Pages

1760 - 1776

Keywords

aspirin, cangrelor, clopidogrel, prasugrel, ticagrelor, vorapaxar, Coronary Artery Disease, Humans, Platelet Aggregation Inhibitors, Risk Assessment